Katia Zahaf

1.2k total citations · 1 hit paper
21 papers, 840 citations indexed

About

Katia Zahaf is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Katia Zahaf has authored 21 papers receiving a total of 840 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Katia Zahaf's work include Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cancer Genomics and Diagnostics (6 papers). Katia Zahaf is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cancer Genomics and Diagnostics (6 papers). Katia Zahaf collaborates with scholars based in France, United States and Portugal. Katia Zahaf's co-authors include Paul Hofman, Véronique Hofman, Marius Ilié, Élodie Long-Mira, Charles‐Hugo Marquette, Jérôme Mouroux, Catherine Butori, Sandra Lassalle, Salomé Lalvée and Coraline Bence and has published in prestigious journals such as Oncogene, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Katia Zahaf

20 papers receiving 835 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

2015 459 citations Marius Ilié, Élodie Long-Mira et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Katia Zahaf

Since Specialization

Citations

This map shows the geographic impact of Katia Zahaf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katia Zahaf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katia Zahaf more than expected).

Fields of papers citing papers by Katia Zahaf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katia Zahaf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katia Zahaf. The network helps show where Katia Zahaf may publish in the future.

Co-authorship network of co-authors of Katia Zahaf

This figure shows the co-authorship network connecting the top 25 collaborators of Katia Zahaf. A scholar is included among the top collaborators of Katia Zahaf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katia Zahaf. Katia Zahaf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations 2025 ·Cancers ·Élodie Long-Mira, (unknown), (unknown), Véronique Hofman, Sandra Lassalle, Jonathan Benzaquen, Jacques Boutros, (unknown), Katia Zahaf, (unknown), Olivier Bordone, (unknown), Christelle Bonnetaud, Charlotte Cohen, Jean‐Philippe Berthet, Charles‐Hugo Marquette, Valérie Vouret‐Craviari, Marius Ilié, Paul Hofman	0
2	Reproducibility of c-Met Immunohistochemical Scoring (Clone SP44) for Non–Small Cell Lung Cancer Using Conventional Light Microscopy and Whole Slide Imaging 2024 ·The American Journal of Surgical Pathology ·(unknown), Véronique Hofman, Emmanuel Chamorey, Renaud Schiappa, Sandra Lassalle, Élodie Long-Mira, Katia Zahaf, Salomé Lalvée, (unknown), Christelle Bonnetaud, (unknown), Marius Ilié, Paul Hofman	1
3	Shifting from Immunohistochemistry to Screen for ALK Rearrangements: Real-World Experience in a Large Single-Center Cohort of Patients with Non-Small-Cell Lung Cancer 2024 ·Cancers ·Marius Ilié, (unknown), (unknown), (unknown), Salomé Lalvée, Olivier Bordone, Katia Zahaf, Christelle Bonnetaud, Kevin Washetine, Sandra Lassalle, Élodie Long-Mira, Simon Heeke, Véronique Hofman, Paul Hofman	5
4	Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort 2023 ·Pathology ·Nuno Jorge Lamas, Sandra Lassalle, Arnaud Martel, Sacha Nahon‐Estève, (unknown), Katia Zahaf, Salomé Lalvée, (unknown), (unknown), Olivier Bordone, Florence Pédeutour, Stéphanie Baillif, Paul Hofman	7
5	Assessment of Different Circulating Tumor Cell Platforms for Uveal Melanoma: Potential Impact for Future Routine Clinical Practice 2023 ·International Journal of Molecular Sciences ·Arnaud Martel, Baharia Mograbi, (unknown), Lauris Gastaud, Salomé Lalvée, Katia Zahaf, (unknown), Sacha Nahon‐Estève, Christelle Bonnetaud, (unknown), Virginie Tanga, Stéphanie Baillif, Corine Bertolotto, Sandra Lassalle, Paul Hofman	6
6	Need for a Dedicated Ophthalmic Malignancy Clinico-Biological Biobank: The Nice Ocular MAlignancy (NOMA) Biobank 2023 ·Cancers ·Arnaud Martel, Lauris Gastaud, Christelle Bonnetaud, Sacha Nahon‐Estève, Kevin Washetine, Olivier Bordone, (unknown), Virginie Tanga, (unknown), (unknown), Maryline Allégra, Salomé Lalvée, Katia Zahaf, Stéphanie Baillif, Corine Bertolotto, Baharia Mograbi, Sandra Lassalle, Paul Hofman	2
7	Lack of correlation between MET and PD-L1 expression in non-small cell lung cancer revealed by comparative study of matched biopsies and surgical resection samples 2023 ·Lung Cancer ·Marius Ilié, Véronique Hofman, (unknown), (unknown), Jonathan Benzaquen, Simon Heeke, Jacques Boutros, Sandra Lassalle, Élodie Long-Mira, Katia Zahaf, Salomé Lalvée, (unknown), Olivier Bordone, Virginie Tanga, Abel Gómez-Caro, Charlotte Cohen, Jean‐Philippe Berthet, Charles‐Hugo Marquette, Paul Hofman	5
8	Analytical validation of automated multiplex chromogenic immunohistochemistry for diagnostic and predictive purpose in non-small cell lung cancer 2022 ·Lung Cancer ·Marius Ilié, (unknown), Élodie Long-Mira, (unknown), Katia Zahaf, Salomé Lalvée, (unknown), Jonathan Benzaquen, Charlotte Cohen, Jean‐Philippe Berthet, Charles‐Hugo Marquette, Sandra Lassalle, Véronique Hofman, Paul Hofman	11
9	Detection of EGFR Mutations From Plasma of NSCLC Patients Using an Automatic Cartridge-Based PCR System 2021 ·Frontiers in Pharmacology ·Simon Heeke, Véronique Hofman, Jonathan Benzaquen, Josiane Otto, Virginie Tanga, Katia Zahaf, Maryline Allégra, Élodie Long-Mira, Sandra Lassalle, Charles‐Hugo Marquette, Marius Ilié, Paul Hofman	13
10	Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) 2020 ·Cancers ·Sandra Lassalle, Véronique Hofman, Simon Heeke, Jonathan Benzaquen, Élodie Long-Mira, M. Poudenx, (unknown), Jacques Boutros, Virginie Tanga, Katia Zahaf, Salomé Lalvée, (unknown), Olivier Bordone, (unknown), Christelle Bonnetaud, Charles‐Hugo Marquette, Marius Ilié, Paul Hofman	17
11	In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients 2019 ·Cancers ·Simon Heeke, Jonathan Benzaquen, Élodie Long-Mira, (unknown), (unknown), Olivier Bordone, Salomé Lalvée, Katia Zahaf, M. Poudenx, Olivier Humbert, Henri Montaudié, (unknown), Madleen Chassang, Thierry Passeron, Hervé Delingette, Charles‐Hugo Marquette, Véronique Hofman, Albrecht Stenzinger, Marius Ilié, Paul Hofman	26
12	Association of combined PD‐L1 expression and tumour‐infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma 2019 ·Journal of the European Academy of Dermatology and Venereology ·Coraline Bence, Véronique Hofman, Emmanuel Chamorey, Élodie Long-Mira, Sandra Lassalle, (unknown), (unknown), Katia Zahaf, (unknown), Henri Montaudié, J.‐P. Lacour, Thierry Passeron, (unknown), Marius Ilié, Paul Hofman	28
13	Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients 2018 ·Lung Cancer ·Alexander T. Falk, (unknown), Nicolas Guibert, Emmanuel Chamorey, Agnès Paquet, (unknown), Coraline Bence, Katia Zahaf, Sylvie Leroy, Charles‐Hugo Marquette, Charlotte Cohen, Baharia Mograbi, Julien Mazières, Véronique Hofman, Patrick Brest, Paul Hofman, Marius Ilié	49
14	PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome 2016 ·Modern Pathology ·Marius Ilié, Alexander T. Falk, Catherine Butori, Emmanuel Chamorey, Christelle Bonnetaud, Élodie Long-Mira, Sandra Lassalle, Katia Zahaf, Nicolas Vénissac, Jérôme Mouroux, Charlotte Cohen, Élisabeth Brambilla, Charles‐Hugo Marquette, Véronique Hofman, Paul Hofman	25
15	Impact of Kras mutant subtypes on PD-L1 expression in lung adenocarcinoma 2016 ·Annals of Oncology ·Alexander T. Falk, (unknown), Lutz Thon, Nicolas Guibert, Véronique Hofman, Katia Zahaf, (unknown), Olivier Bordone, Virginie Tanga, Kevin Washetine, Charlotte Cohen, Nicolas Vénissac, Jérôme Mouroux, Charles‐Hugo Marquette, Patrick Brest, Marius Ilié, Paul Hofman	2
16	Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies breakdown → 2015 ·Annals of Oncology ·Marius Ilié, Élodie Long-Mira, Coraline Bence, Catherine Butori, Sandra Lassalle, L. Bouhlel, (unknown), Katia Zahaf, Salomé Lalvée, Kevin Washetine, Jérôme Mouroux, Nicolas Vénissac, M. Poudenx, Josiane Otto, Jean‐Christophe Sabourin, Charles‐Hugo Marquette, Véronique Hofman, Paul Hofman	459
17	NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2 2015 ·Oncogene ·Gian Marco De Donatis, Elodie Le Pape, (unknown), Yann Chéli, Véronique Hofman, Paul Hofman, (unknown), Katia Zahaf, Philippe Bahadoran, Stéphane Rocchi, Corine Bertolotto, Robert Ballotti, Thierry Passeron	45
18	L’accréditation selon la norme ISO 15189 d’un laboratoire de pathologie et de génétique somatique (LPCE, CHU de Nice) : retour d’expérience 2013 ·Annales de Pathologie ·Kevin Washetine, Élodie Long-Mira, Véronique Hofman, Sandra Lassalle, Marius Ilié, (unknown), Christelle Bonnetaud, Olivier Bordone, (unknown), Éric Selva, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Katia Zahaf, (unknown), Paul Hofman	13
19	Accréditation de l’activité de pathologie moléculaire selon la norme ISO 15189. Principales étapes à respecter et principaux écueils possibles 2013 ·Annales de Pathologie ·Élodie Long-Mira, Véronique Hofman, Marius Ilié, Kevin Washetine, (unknown), Christelle Bonnetaud, Olivier Bordone, (unknown), (unknown), Sandra Lassalle, Éric Selva, Katia Zahaf, Aude Lamy, Jean‐Christophe Sabourin, Paul Hofman	9
20	ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma 2012 ·Annals of Oncology ·Marius Ilié, Élodie Long-Mira, Catherine Butori, Véronique Hofman, Céline Coëlle, (unknown), Katia Zahaf, Charles‐Hugo Marquette, Jérôme Mouroux, Patrizia Paterlini-Bréchot, Paul Hofman	113

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact